Results 191 to 200 of about 530,731 (290)

Unmasking a Composite Lymphoma: Follicular Lymphoma Emerging After Bispecific Antibody Treatment of Marginal Zone Lymphoma. [PDF]

EJHaem
Orosco-Ttamina AL, Zhou J, Biondo J, Hossain F, Viswanatha D, Greipp PT, Lewis N, Munoz J.   +7 more
europepmc   +1 more source

Life-threatening anaphylactic shock induced by cadonilimab (AK104), a PD-1/CTLA-4 bispecific antibody: a case report. [PDF]

Front Pharmacol
Zheng Z, Li J, Huang Q.
europepmc   +1 more source

A PD1‐CD137L Fusion Protein More Potently Enhances Anti‐Tumour Immune Responses Than Targeting PD‐L1 and CD137 Separately

Immunology, EarlyView.
A PD1‐CD137L fusion protein converts the immunoinhibitory PD‐L1 to an immunostimulatory signal and is more effective than targeting PD‐L1 and CD137 separately. ABSTRACT Tumour immune evasion frequently involves PD‐L1‐mediated inhibition of T cell activity, limiting the efficacy of PD1/PD‐L1 blockade, particularly in PD‐L1‐low or immunologically ‘cold ...
Runze Xia, Emily Pauline Nickles, Yu Mei, Thamizhanban Manoharan, Yi Tian Png, Beijia Liu, Rui Sun, Kang Yi Lee, Gloryn Chia, Chwee Ming Lim, Herbert Schwarz   +10 more
wiley   +1 more source

Bispecific antibody AP402 targets p95HER2 and induces costimulation through CD137 to improve efficacy for HER2-positive tumors. [PDF]

Mol Med
Huang PL, Hsieh HT, Kan HT, Hsu CH, Huang KM, Chen HY, Chen TN, You JJ.   +7 more
europepmc   +1 more source

Pathophysiology and emerging treatments for dermographic, cholinergic and cold urticaria

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This review illustrates key proposed mast cell‐mediated activation pathways in dermographic, cholinergic and cold urticaria, highlighting IgE‐dependent and ‐independent mechanisms. These pathways are increasingly targeted by emerging drugs, aiming to interrupt mast cell activation and mediator release, offering more precise, mechanism‐based treatment ...
Mojca Bizjak‐Suran, Matjaž Fležar, Manuel Pedro Pereira   +2 more
wiley   +1 more source

T cell dysfunction associated with repeated CAR-T cell manufacturing failure following prolonged bispecific antibody exposure: a case report. [PDF]

Leuk Res Rep
Henry SJW, Pfeffer K, Shim KG, Meermeier EW, Feng F, Wiedmeier JE, Chhabra S, Bergsagel PL, Fonseca R, Wonnaparhown AM, Gustafson MP.   +10 more
europepmc   +1 more source

Periodontitis and Rheumatoid Arthritis—Mechanistic Evidence

Journal of Periodontal Research, EarlyView.
Periodontitis and rheumatoid arthritis are linked via the two‐hit model whereby early periodontal inflammation can lead to autoantibody production capable of interacting with inflamed synovial tissues. Subsequent systemic inflammation can exacerbate the periodontal inflammatory response and bacterial dysbiosis leading to further autoantibody production
Mark Bartold, Chia Wei Cheah, Rathna Devi Vaithilingam   +2 more
wiley   +1 more source

CLEC5A/TLR2 bispecific antibody suppresses dengue virus-induced pro-inflammatory cytokines production from macrophages. [PDF]

J Biomed Sci
Wang SH, Kuo WT, Cheng D, Sung PS, Shih SR, Hsieh SL, Wang JR.   +6 more
europepmc   +1 more source

Physical Activity, Bleeding Incidence and Health‐Related Quality of Life, in Patients With Haemophilia A Without Inhibitors, Treated With Emicizumab: A Post‐Hoc Descriptive Analysis of the Power Study Data

Haemophilia, EarlyView.
Matteo Nicola Dario Di Minno, Berardino Pollio, Ezio Zanon, Gaetano Giuffrida, Sara Bendinelli, Raffaella Perrone, Giancarlo Castaman, the POWER study sites group   +7 more
wiley   +1 more source

Right dose, right patient: Clinician‐led implementation of a national cross‐specialty strategy for immunoglobulin stewardship

Vox Sanguinis, EarlyView.
Abstract Background and Objectives Global demand for immunoglobulin (Ig) continues to rise, driven by expanding clinical indications and limited plasma supply. In England, use increased annually despite earlier demand‐management efforts, with substantial regional variation and prescribing for indications lacking evidence of benefit.
Claire Bethune, Michael P. Lunn, Mark Foster, Rob Hollingsworth, Darryn Boardman, Siraj A. Misbah   +5 more
wiley   +1 more source